Mirtazapin Orion (Mirtazapine)

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders.

• Major depressive disorder: reduces depressive symptoms and improves functional outcomes.
• Treatment‑resistant depression: may be considered when first‑line agents are insufficient.
• Depressive episodes in bipolar disorder (adjunct): helps manage the depressive phase alongside mood stabilizers.
• Anxiety associated with depression: can alleviate concurrent anxiety symptoms.
• Insomnia related to depression: its antihistamine effect may improve sleep quality.
• Appetite loss in depression: may stimulate appetite and promote weight gain.

• Mirtazapine antagonizes central presynaptic α2‑adrenergic receptors, increasing the release of norepinephrine and serotonin. It also blocks postsynaptic 5‑HT2 and 5‑HT3 receptors while strongly inhibiting histamine H1 receptors. The combined effect enhances noradrenergic and serotonergic neurotransmission and produces sedative and appetite‑stimulating properties, contributing to its antidepressant activity. By preventing feedback inhibition, it amplifies monoamine signaling in key brain regions involved in mood regulation.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Sedation or drowsiness, often pronounced after the first few doses and may improve with continued therapy.
• Increased appetite and weight gain, which can be noticeable over weeks and may require dietary counseling.
• Dry mouth, leading to discomfort, difficulty swallowing, and potential dental issues if persistent.
• Constipation, which can be managed with dietary fiber, adequate hydration, and occasional laxatives.

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia, presenting with fever, sore throat, or increased infection risk and requiring immediate medical evaluation.
• Serotonin syndrome, characterized by agitation, hyperthermia, tremor, sweating, and autonomic instability when combined with other serotonergic agents, necessitating urgent care.

When prescribing Mirtazapine, clinicians should consider several precautionary measures to ensure safe use.

• Monitor weight: patients may experience rapid weight gain, requiring regular assessment.
• Assess for suicidal ideation: especially during the initial treatment period or dosage changes.
• Evaluate hepatic function: dose adjustment may be needed in severe liver impairment.
• Avoid abrupt discontinuation: tapering is recommended to reduce the risk of withdrawal symptoms.
• Caution in elderly: increased sensitivity to sedation and orthostatic hypotension.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use can precipitate hypertensive crisis or serotonin syndrome.
• Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increase risk of serotonin syndrome.
• CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedative effects.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels.
• CYP inducers (e.g., carbamazepine, rifampin): may reduce therapeutic effect.
• Antihistamines: additive anticholinergic side effects may occur.